Publications

Breakthrough treatments for Ebola virus disease, but no access-what went wrong, and how can we do better?

Abstract

Three years since proving effective for Ebola virus disease in a clinical trial, two breakthrough treatments are registered and stockpiled in the USA but still not registered and generally available in the countries most affected by this deadly infecti

Torreele E Boum Y Adjaho I Alé FGB Issoufou SH Harczi G Okonta C Olliaro P
The Lancet. Infectious diseases 2023 Jan 19; . doi: 10.1016/S1473-3099(22)00810-6. Epub 2023 01 19

Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis.

Abstract

BACKGROUND: Evidence on the comparative performance of purified protein derivative tuberculin skin tests (TST) and interferon-gamma release assays (IGRA) for predicting incident active tuberculosis (TB) remains conflicting.

Yohhei Hamada Rishi K. Gupta Matteo Quartagno Abbie Izzard Carlos Acuna-Villaorduna Neus Altet et al.
The lancet. Vol 56 February, 2023. Published online January 05, 2023. doi: 10.1016/j.eclinm.2022.101815
Tuberculosis

Genomic Microevolution of Vibrio cholerae O1, Lake Tanganyika Basin, Africa.

Abstract

Africa's Lake Tanganyika basin is a cholera hotspot. During 2001-2020, Vibrio cholerae O1 isolates obtained from the Democratic Republic of the Congo side of the lake belonged to 2 of the 5 clades of the AFR10 sublineage.

Hounmanou YMG Njamkepo E Rauzier J Gallandat K Jeandron A Kamwiziku G Porten K Luquero F Abedi AA Rumedeka BB Miwanda B Michael M Okitayemba PW Saidi JM Piarroux R Weill FX Dalsgaard A Quilici ML
Emerging infectious diseases 2023 Jan ; 29(1); . doi: 10.3201/eid2901.220641. Epub 2022 12 28
Africa. Emerg Infect Dis. 2023 Jan [date cited]. https://doi.org/10.3201/eid2901.220641 African Great Lakes Region Burundi Democratic Republic of Congo Gallandat K Jeandron A Kamwiziku G Lake Tanganyika Lake Tanganyika Basin Njamkepo E Rauzier J Suggested citation for this article: Hounmanou YMG Tanzania Vibrio cholerae Zambia bacteria cholera et al. Genomic microevolution of Vibrio cholerae O1 genomics neglected tropical diseases

Novel FujiLAM assay to detect tuberculosis in HIV-positive ambulatory patients in four African countries: a diagnostic accuracy study.

Abstract

BACKGROUND: Development of rapid biomarker-based tests that can diagnose tuberculosis using non-sputum samples is a priority for tuberculosis control.

Helena Huerga Mathieu Bastard Alex Vicent Lubega Milcah Akinyi Natalia Tamayo Antabak Liesbet Ohler et al.
The Lancet Global Health. Volume 11, Issue 1, January 2023, Pages e126-e135
Tuberculosis HIV

Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein.

Abstract

Sero-surveillance can monitor and project disease burden and risk. However, SARS-CoV-2 antibody test results can produce false positive results, limiting their efficacy as a sero-surveillance tool.

Sarah Lapidus Feimei Liu Arnau Casanovas-Massana Yile Dai John D. Huck Carolina Lucas et al.
Sci Rep. 2022; 12: 22175. Published online 2022 Dec 22. doi: 10.1038/s41598-022-26709-7
Malaria Infectious-disease diagnostics Viral infection

Snakebite envenoming at MSF: A decade of clinical challenges and antivenom access issues.

Abstract

The medical humanitarian organization Médecins Sans Frontières (MSF) provides medical care in more than 70 countries and admits more than 7000 cases of snakebite in its facilities each year.

Julien Potet Saschveen Singh Koert Ritmeijer Kasaye Sisay Gabriel Alcoba Fabienne Jouberton et al.
Toxicon: X. Volume 17, March 2023, 100146. Published online 2022 Dec 21. doi: 10.1016/j.toxcx.2022.100146
snakebite Antivenoms

Effect of systematic tuberculosis detection on mortality in young children with severe pneumonia in countries with high incidence of tuberculosis: a stepped-wedge cluster-randomised trial.

Abstract

BACKGROUND: Tuberculosis diagnosis might be delayed or missed in children with severe pneumonia because this diagnosis is usually only considered in cases of prolonged symptoms or antibiotic failure.

Marcy O Wobudeya E Font H Vessière A Chabala C Khosa C Taguebue JV Moh R Mwanga-Amumpaire J Lounnas M Mulenga V Mavale S Chilundo J Rego D Nduna B Shankalala P Chirwa U De Lauzanne A Dim B Tiogouo Ngouana E Folquet Amorrissani M Cisse L Amon Tanoh Dick F Komena EA Kwedi Nolna S Businge G Natukunda N Cumbe S Mbekeka P Kim A Kheang C Pol S Maleche-Obimbo E Seddon JA Mao TE Graham SM Delacourt C Borand L Bonnet M
The Lancet. Infectious diseases 2022 Nov 14; . doi: 10.1016/S1473-3099(22)00668-5. Epub 2022 11 14

Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion.

Abstract

BACKGROUND: Conversion of sputum culture from positive to negative for M. tuberculosis is a key indicator of treatment response. An initial positive culture is a pre-requisite to observe conversion.

Rodriguez CA Lodi S Horsburgh CR Bastard M Hewison C Huerga H Khan M Khan PY Khan U Oyewusi L Padayachee S Mitnick CD Franke MF
PloS one 2022 ; 17(11); . doi: 10.1371/journal.pone.0276457. Epub 2022 11 10